Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4066689rdf:typepubmed:Citationlld:pubmed
pubmed-article:4066689lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:4066689lifeskim:mentionsumls-concept:C0085201lld:lifeskim
pubmed-article:4066689lifeskim:mentionsumls-concept:C0439659lld:lifeskim
pubmed-article:4066689lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:4066689pubmed:issue29lld:pubmed
pubmed-article:4066689pubmed:dateCreated1986-1-16lld:pubmed
pubmed-article:4066689pubmed:abstractTextThe origin and the functional significance of apo-A-I polymorphism in man has been investigated. Together with proapo-A-I (identified as A-I1 of the polymorphic series), four other isoforms are found in human plasma, namely A-I2, A-I3, A-I4, and A-I5. A-I3 is the "mature" product of proapo-A-I conversion in plasma. In this study we provide evidence that the other, more acidic, mature apo-A-I isoproteins are derived from A-I3 by a stepwise deamidation process. This conclusion is based on the following observations. 1) Incubation of A-I3 or A-I4, either free or associated with high density lipoprotein, produces a series of more acidic isoproteins corresponding to the sequence found in plasma. The conversion process fits in well with a first order reaction, and A-I3 to A-I4 conversion occurs virtually at the same rate as A-I4 to A-I5 conversion. 2) A-I3 and A-I4 have the same NH2- and C-terminal residues. 3) Formation of apo-A-I acidic isoproteins is accompanied by liberation of ammonia. In order to investigate whether deamidation of apo-A-I results in the production of forms which have different catabolism, a series of turnover studies was carried out in normal volunteers. A-I3 and A-I4 residence times in plasma were, respectively, 3.50 +/- 0.16 and 3.00 +/- 0.10 days (mean +/- S.E.; n = 3). Degradation rate of A-I3 was 8.81 +/- 0.69 mg/kg/day and that of A-I4 was 1.66 +/- 0.15 mg/kg/day (mean +/- S.E.; n = 3). Conversion of A-I3 to A-I4 and A-I4 to A-I5 occurred at the same rate in vivo as that observed in vitro. These results are consistent with the concept that A-I3 is the precursor to the other mature apo-A-I isoforms in plasma. A-I3 is the major isoform through which apo-A-I is eliminated from plasma.lld:pubmed
pubmed-article:4066689pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:languageenglld:pubmed
pubmed-article:4066689pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:citationSubsetIMlld:pubmed
pubmed-article:4066689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4066689pubmed:statusMEDLINElld:pubmed
pubmed-article:4066689pubmed:monthDeclld:pubmed
pubmed-article:4066689pubmed:issn0021-9258lld:pubmed
pubmed-article:4066689pubmed:authorpubmed-author:GottoA MAMJrlld:pubmed
pubmed-article:4066689pubmed:authorpubmed-author:KrishnanSSlld:pubmed
pubmed-article:4066689pubmed:authorpubmed-author:RohdeM FMFlld:pubmed
pubmed-article:4066689pubmed:authorpubmed-author:GhiselliGGlld:pubmed
pubmed-article:4066689pubmed:authorpubmed-author:TanenbaumSSlld:pubmed
pubmed-article:4066689pubmed:issnTypePrintlld:pubmed
pubmed-article:4066689pubmed:day15lld:pubmed
pubmed-article:4066689pubmed:volume260lld:pubmed
pubmed-article:4066689pubmed:ownerNLMlld:pubmed
pubmed-article:4066689pubmed:authorsCompleteYlld:pubmed
pubmed-article:4066689pubmed:pagination15662-8lld:pubmed
pubmed-article:4066689pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:meshHeadingpubmed-meshheading:4066689-...lld:pubmed
pubmed-article:4066689pubmed:year1985lld:pubmed
pubmed-article:4066689pubmed:articleTitleOrigin of apolipoprotein A-I polymorphism in plasma.lld:pubmed
pubmed-article:4066689pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:4066689pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:4066689pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:4066689lld:pubmed